1. Scrip
  2. >>Focus On Asia
  3. >>China

Gene Editing In China: EdiGene Raises Fresh Funds, Aims For First IND

'Great Leap' From Gene-Edited Babies to One-Time Cures

 
• By Brian Yang

With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.

Gene editiing
GENE EDITING FIRM EDIGENE RAISES NEW FUNDS, PLANS FIRST IND IN CHINA • Source: Shutterstock

Spurred by gene therapy approvals and driven by patient demand, EdiGene Inc is betting on becoming China’s leading gene editing therapy developer, aided by the country’s determination to progress domestically developed novel therapies with their own intellectual property rights.

Founded by Peking University professor Wensheng Wei in 2015, the Beijing-based company has undergone a transformation since 2018 and now has three therapies in development

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Focus On Asia